These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17047132)

  • 21. Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.
    Callens S; Bottieau E; Michielsen P; Colebunders R
    AIDS; 2004 Jan; 18(1):131. PubMed ID: 15090841
    [No Abstract]   [Full Text] [Related]  

  • 22. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
    Kartal ED; Alpat SN; Ozgunes I; Usluer G
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):817-20. PubMed ID: 17700271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interstitial pneumonia recurrence during chronic hepatitis C treatment.
    Renou C; Germain S; Harafa A; Martin S; Larroque O; Muller P; Bertrand JJ; Halfon P
    Am J Gastroenterol; 2005 Jul; 100(7):1625-6. PubMed ID: 15984999
    [No Abstract]   [Full Text] [Related]  

  • 24. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C.
    Atug O; Akin H; Yilmaz Y; Sari M; Tozun N
    J Gastrointestin Liver Dis; 2009 Jun; 18(2):256. PubMed ID: 19565068
    [No Abstract]   [Full Text] [Related]  

  • 26. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin.
    Cauli C; Serra G; Chessa L; Balestrieri C; Scioscia R; Lai ME; Farci P
    Haematologica; 2006 Jun; 91(6 Suppl):ECR26. PubMed ID: 16785129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-induced thyroid dysfunction--not always transient.
    Wong VW; Cheng AY; Chan HL
    J Gastroenterol Hepatol; 2009 Jun; 24(6):938-40. PubMed ID: 19638076
    [No Abstract]   [Full Text] [Related]  

  • 28. Acute pancreatitis associated with the use of peginterferon.
    Ozdogan O; Tahan V; Cincin A; Imeryuz N; Tozun N
    Pancreas; 2007 May; 34(4):485-7. PubMed ID: 17446854
    [No Abstract]   [Full Text] [Related]  

  • 29. Peginterferon and ribavirin for hepatitis C.
    Ben Salem C; Hmouda H; Bouraoui K
    N Engl J Med; 2007 Mar; 356(12):1270; author reply 1271. PubMed ID: 17380578
    [No Abstract]   [Full Text] [Related]  

  • 30. Life-threatening thyrotoxicosis induced by combination therapy with PEG-interferon and ribavirin in chronic hepatitis C.
    Lin YQ; Wang X; Murthy MS; Agarwala S
    Endocr Pract; 2005; 11(2):135-9. PubMed ID: 15901529
    [No Abstract]   [Full Text] [Related]  

  • 31. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Yang WS; Chu PL; Liu CH; Chung GB; Wu KD
    J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
    [No Abstract]   [Full Text] [Related]  

  • 32. Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C.
    Alves Couto C; Costa Faria L; Dias Ribeiro D; de Paula Farah K; de Melo Couto OF; de Abreu Ferrari TC
    Liver Int; 2006 Dec; 26(10):1294-7. PubMed ID: 17105597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Combination therapy for chronic viral hepatitis C].
    Zeuzem S
    Dtsch Med Wochenschr; 2003 Feb; 128(8):370-4. PubMed ID: 12594622
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
    New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C.
    Yurci A; Guven K; Torun E; Gursoy S; Baskol M; Akgun H; Ozbakir O; Yucesoy M
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):811-5. PubMed ID: 17700270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 37. What caused this lingual hyperpigmentation in a patient with chronic hepatitis C?
    Radha Krishna Y; Itha S
    Liver Int; 2010 Mar; 30(3):416. PubMed ID: 19422481
    [No Abstract]   [Full Text] [Related]  

  • 38. [Acute pancreatitis during treatment for chronic viral hepatitis C].
    Kabbaj N; Sentissi S; Guedira MM; Mohammadi M; Benaïssa A; Amrani N
    Gastroenterol Clin Biol; 2008 Mar; 32(3):232-3. PubMed ID: 18378105
    [No Abstract]   [Full Text] [Related]  

  • 39. Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy.
    Homoncik M; Sieghart W; Formann E; Schmid M; Ferenci P; Gangl A; Jilma B; Peck-Radosavljevic M
    Am J Gastroenterol; 2006 Oct; 101(10):2275-82. PubMed ID: 17032193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rosacea fulminans associated with pegylated interferon alpha-2B and ribavirin therapy.
    Jensen SL; Holmes R
    J Drugs Dermatol; 2003 Oct; 2(5):554-6. PubMed ID: 14558405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.